Biodexa Pharmaceuticals
- Country
- 🇨🇦Canada
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 21
- Market Cap
- -
- Website
- http://www.biodexapharma.com
- Introduction
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
- Conditions
- Recurrent Glioblastoma
- Interventions
- Device: Programmable pump and catheter system
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Biodexa Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT05324501
- Locations
- 🇺🇸
Baptist MD Anderson, Jacksonville, Florida, United States
🇺🇸Duke University Hospital, Durham, North Carolina, United States
News
Biodexa Initiates Phase 2 Trial of Tolimidone for Type 1 Diabetes Treatment
Biodexa Pharmaceuticals has enrolled the first patient in a Phase 2 study evaluating tolimidone, a selective Lyn kinase activator, for Type 1 diabetes treatment.
FDA Grants Fast Track Status to eRapa for Familial Adenomatous Polyposis Treatment
Biodexa Pharmaceuticals' eRapa, a novel formulation of rapamycin, receives FDA Fast Track Designation for treating familial adenomatous polyposis (FAP), addressing a critical unmet medical need.
MTX110 Shows Promise in Recurrent Glioblastoma: Phase 1 Data
MTX110, a novel formulation of panobinostat, demonstrates potential survival benefits in patients with recurrent glioblastoma in the phase 1 MAGIC-1 study.
Biodexa's MTX110 Shows Promise in Recurrent Glioblastoma Phase 1 Trial
Biodexa Pharmaceuticals' MTX110 demonstrates encouraging progression-free survival (PFS) and overall survival (OS) data in recurrent glioblastoma (rGBM) patients.